Cardiology – Page 34

Low-Dose Digoxin Enhances Cardiac Function in Heart Failure with Preserved EF and Atrial Fibrillation: Insights from the RATE-AF Trial

By MedXY 09/02/2025

The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer adverse events.

Cardiology news Specialties

Decoding Heart Failure Risk: Integrated Systolic and Diastolic Function Trajectories and Proteomic Insights

By MedXY 09/02/2025

Bayesian modelling of combined systolic and diastolic function trajectories in older adults reveals distinct patterns predicting heart failure subtypes and identifies potential proteomic targets for therapy.

Cardiology news Specialties

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

By MedXY 09/02/2025

This study integrates longitudinal systolic and diastolic cardiac function measures using Bayesian modeling to identify trajectories associated with distinct heart failure subtypes and proteomic signatures, enhancing risk prediction and therapeutic target discovery.

AI Cardiology news Specialties

Harnessing Mobile Technology for Early Heart Failure Detection: Insights from the ECHOS3 Registry in Primary Care

By MedXY 09/02/2025

Mobile app-assisted screening in primary care settings identified new heart failure cases in one-third of at-risk patients, especially those with preserved ejection fraction, highlighting a promising route for early diagnosis.

Cardiology Family Medicine & Nutrition news Specialties

Lower High Blood Lipids Risk: Avoid Common Pitfalls and Embrace 4 Healthy Habits

By MedXY 09/02/2025

High blood lipids impact over 300 million people in China, often silently increasing cardiovascular risk. Learn to avoid common misconceptions and adopt four scientifically backed habits to improve your blood lipid profile and heart health.

Cardiology news Specialties

Clopidogrel Surpasses Aspirin: Comprehensive Meta-Analysis Shows Superior Secondary Prevention in Coronary Artery Disease

By MedXY 09/02/2025

A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.

Cardiology Clinical Updates Gastroenterology Specialties

Routine Helicobacter pylori Screening Post-Myocardial Infarction: Insights from the HELP-MI SWEDEHEART Trial

By MedXY 09/02/2025

Routine H. pylori screening after acute myocardial infarction does not significantly reduce upper gastrointestinal bleeding incidence; targeted screening in anemia or kidney failure subgroups may offer benefit.

Cardiology Clinical Updates Gastroenterology news Specialties

Routine Helicobacter pylori Screening Post-Myocardial Infarction: Insights from the HELP-MI SWEDEHEART Trial

By MedXY 09/02/2025

In a large Swedish cluster-randomized trial, routine Helicobacter pylori screening after acute myocardial infarction did not significantly reduce upper gastrointestinal bleeding, though high-risk subgroups may benefit.

Cardiology Clinical Updates Radiology Specialties

FFR-Guided Complete Revascularization Enhances Outcomes in NSTEMI with Multivessel Disease: Insights from the SLIM Trial

By MedXY 09/01/2025

The SLIM trial demonstrates that fractional flow reserve–guided complete revascularization during the index procedure significantly reduces major adverse events at one year in patients with NSTEMI and multivessel disease, primarily by lowering repeat revascularizations.

Cardiology Specialties

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

By MedXY 09/01/2025

The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies in selected patients.

Cardiology news Public Health Respiratory Specialties

Bivalent RSV Prefusion F Protein Vaccine: A Potential Strategy to Reduce Cardiovascular Hospitalizations in Older Adults

By MedXY 09/01/2025

The DAN-RSV trial demonstrates that RSV vaccination significantly lowers all-cause cardiorespiratory hospitalizations among older adults, suggesting vaccines may reduce infection-triggered cardiovascular complications and benefit chronic disease management.

Cardiology Clinical Updates news Specialties

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

By MedXY 08/31/2025

Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.

Cardiology Medical News news Specialties

TAVI vs SAVR at Low–Intermediate Risk: What the New Individual‑Patient Meta‑Analysis Means for Practice

By MedXY 08/31/2025

A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team decisions, and follow‑up priorities.

Cardiology news Specialties

Clonal Hematopoiesis as a Novel Risk Factor for Myocarditis and Pericarditis: Insights from the UK Biobank

By MedXY 08/31/2025

Clonal hematopoiesis of indeterminate potential (CHIP) is linked to a significantly increased risk of new-onset myocarditis and pericarditis, especially involving DNMT3A and TET2 mutations, highlighting a potential target for preventing inflammatory heart diseases.

Cardiology Clinical Updates news Specialties

Personalized Accelerated Physiologic Pacing Shows Promise in HFpEF: Insights from the myPACE Trial Extension

By MedXY 08/31/2025

Personalized increased pacing rates in patients with HFpEF and physiologic pacemakers may reduce adverse events and improve event-free survival, per a 4-year observational extension of the myPACE randomized trial.

Cardiology Clinical Updates General Surgery news Specialties

Reducing Infection Risk in Repeat CIED Surgery with Iodine-Impregnated Drapes: Insights from a Randomized Clinical Trial

By MedXY 08/31/2025

A randomized trial demonstrates that iodine-impregnated drapes significantly reduce pocket contamination and cardiac implantable electronic device infections in repeat surgeries, offering a simple, cost-effective prophylactic intervention.

Cardiology Clinical Updates Family Medicine & Nutrition news Specialties

Cardiologists and Lifestyle Medicine: Bridging the Gap Between Recommendation and Practice

By MedXY 08/31/2025

A recent survey reveals that most US cardiologists inconsistently adhere to lifestyle recommendations, especially dietary and physical activity guidelines, despite endorsing them for cardiovascular health.

Cardiology news Radiology Specialties

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

By MedXY 08/30/2025

This Danish cohort study demonstrates that increased epicardial adipose tissue volume independently elevates the risk of new-onset atrial fibrillation, highlighting the importance of fat distribution beyond BMI in cardiovascular risk assessment.

Cardiology Clinical Updates news Specialties

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

By MedXY 08/30/2025

The DIGIT-HF trial sheds new light on digitoxin's role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.

Cardiology news Specialties

Digitoxin Revisited: A Renewed Therapeutic Avenue for Advanced Heart Failure Patients

By MedXY 08/30/2025

The DIGIT-HF trial reveals that adding low-dose digitoxin to standard heart failure treatment reduces hospitalization and all-cause mortality in symptomatic HFrEF patients, highlighting a potential resurgence for this historic cardiac glycoside under strict dosing protocols.